Evidence map›Paper›PMID 42433246›Full record

ArticleTranslational lung cancer research2026

Osalmid inhibits lung adenocarcinoma progression and enhances EGFR-TKI responses: a preclinical and translational study.

Leilei Wu, Zhijian Xu, Wenmei Jiang, Shangshang Ma, Diego Gonzalez-Rivas, Weiliang Zhu, Dong Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leilei Wu *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhijian Xu *CAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Wenmei Jiang *Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Shangshang MaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Diego Gonzalez-RivasDepartment of Thoracic Surgery, Klinikum Ernst von Bergmann, Academic Hospital of the Charité-Universitätsmedizin Humboldt University Berlin, Potsdam, Germany.
Weiliang ZhuCAS Key Laboratory of Receptor Research; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Dong XieDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Therapeutic resistance to current treatment strategies indicates the need for more effective agents to treat lung adenocarcinoma (LUAD). RRM2 dysregulation has been implicated in LUAD progression and therapeutic resistance. However, whether pharmacological inhibition of ribonucleotide reductase regulatory subunit M2 (RRM2) by osalmid may suppress LUAD growth and enhance epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) responses remains unclear. We sought to explore the antitumor effects of osalmid and investigate potential combinatorial approaches with third-generation EGFR-TKIs to treat LUAD patients with Methods: Patient data were used to analyze survival based on Results: Patients with high Conclusions: Our findings suggest that osalmid exerts antitumor activity in LUAD and may enhance EGFR-TKI responses, particularly in EGFR-mutant or RRM2-dependent contexts. Further validation in biomarker-selected models is warranted.

Indexed as

EGFR mutationepidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)lung adenocarcinoma (LUAD)osalmidribonucleotide reductase regulatory subunit M2 (RRM2)

Identifiers

PMID42433246
PMCPMC13351902

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.